3-氨基-1-茚满醇 | 403672-07-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 3-氨基-1-茚满醇
• 英文名称: 3-amino-1H-indan-1-ol
• 英文别名: 3-amino-1-indanol；3-amino-2,3-dihydro-1H-inden-1-ol
• CAS: 403672-07-1
• 化学式: C₉H₁₁NO
• 分子量: 149.192
• InChiKey: PRVIGUZMXLBANS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-氨基-1-茚满醇 在 4-二甲氨基吡啶 、 potassium carbonate 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 27.0h， 生成 (+/-)-trans-3-(N,N-dipropargylamino)-1-indanyl acetate
  参考文献：
  名称：

  TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases

  摘要：

  The interest on computational techniques for the discovery of neuroprotective drugs has increased due to recent fail of important clinical trials. In fact, there is a huge amount of data accumulated in public databases like CHEMBL with respect to structurally heterogeneous series of drugs, multiple assays, drug targets, and model organisms. However, there are no reports of multi-target or multiplexing Quantitative Structure-Property Relationships (mt-QSAR/mx-QSAR) models of these multiplexing assay outcomes reported in CHEMBL for neurotoxicity/neuroprotective effects of drugs. Accordingly, in this paper we develop the first mx-QSAR model for multiplexing assays of neurotoxicity/neuroprotective effects of drugs. We used the method TOPS-MODE to calculate the structural parameters of drugs. The best model found correctly classified 4393 out of 4915 total cases in both training and validation. This is representative of overall train and validation Accuracy, Sensitivity, and Specificity values near to 90%, 98%, and 80%, respectively. This dataset includes multiplexing assay endpoints of 2217 compounds. Every one compound was assayed in at least one out of 338 assays, which involved 148 molecular or cellular targets and 35 standard type measures in 11 model organisms (including human). The second aim of this work is the exemplification of the use of the new mx-QSAR model with a practical case of study. To this end, we obtained again by organic synthesis and reported, by the first time, experimental assays of the new 1,3-rasagiline derivatives 3 different tests: assay (1) in absence of neurotoxic agents, (2) in the presence of glutamate, and (3) in the presence of H2O2. The higher neuroprotective effects found for each one of these assays were for the stereoisomers of compound 7: compound 7b with protection = 23.4% in assay (1) and protection = 15.2% in assay (2); and for compound 7a with protection = 46.2% in assay (3). Interestingly, almost all compounds show protection values >10% in assay (3) but not in the other 2 assays,. After that, we used the mx-QSAR model to predict the more probable response of the new compounds in 559 unique pharmacological tests not carried out experimentally. The results obtained are very significant because they complement the pharmacological studies of these promising rasagiline derivatives. This work paves the way for further developments in the multi-target/multiplexing screening of large libraries of compounds potentially useful in the treatment of neurodegenerative diseases. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.01.035
• 作为产物：
  描述：

  3-氨基茚-1-酮盐酸盐 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 3-氨基-1-茚满醇
  参考文献：
  名称：

  高效的顺式和反式3-氨基茚满-1-醇的生物催化拆分：对映纯正交保护的顺式和反式茚满-1,3-二胺的合成。

  摘要：

  对映纯1,3-双官能化的茚满衍生物的有效化学合成已经实现。相应的顺式和反式N保护的氨基醇已成功地通过脂肪酶B乙酰化而分离，脂肪酶B是一种从南极假丝酵母分离的生物催化剂。以非常好的化学收率和ee值（> 99％）获得了所有可能的异构体。这些化合物的效用随后通过使用Mitsunobu反应制备正交保护的顺式和反式茚满-1,3-二胺得到了证明。反式异构体和去对称的顺式非对映体的对映体均以对映纯形式制备。通过结合NMR技术和分子模型，证明了Mitsunobu反应过程中构型的完全转化。

  DOI：

  10.1002/chem.200306070

文献信息

• DIAMINOPROPANE DERIVED MACROCYCLES AS INHIBITORS OF BETA AMYLOID PRODUCTION
  申请人：Marcin Lawrence R.

  公开号：US20080194535A1

  公开（公告）日：2008-08-14

  There is provided a series of macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , m, n, W, X, Y, Z and L as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供一系列宏环脂肪二胺丙烷化合物的化学式（I）或其立体异构体；或其药用盐， 其中R1，R2，R3，m，n，W，X，Y，Z和L如本文所定义，它们的药物组合物和使用方法。这些新化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地说，抑制Aβ-肽的产生。本公开涉及对治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物，如阿尔茨海默病和其他受抗淀粉样活性影响的疾病。
• [EN] COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：REDX PHARMA PLC

  公开号：WO2017103611A1

  公开（公告）日：2017-06-22

  This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

  这项发明涉及新颖的化合物。该发明的化合物是酪氨酸激酶抑制剂。具体来说，该发明的化合物可用作布鲁顿氏酪氨酸激酶（BTK）的抑制剂。该发明还考虑了利用这些化合物治疗通过抑制布鲁顿氏酪氨酸激酶可治疗的疾病，例如癌症、淋巴瘤、白血病和免疫性疾病。
• Macrocyclic diaminopropanes as beta-secretase inhibitors
  申请人：Marcin R. Lawrence

  公开号：US20070037868A1

  公开（公告）日：2007-02-15

  There is provided a series of novel macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 4 , R 5 , n, L, Z, and as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列新型的大环二胺丙烷化合物，其化学式为（I）或其立体异构体；或其药学上可接受的盐，其中R1、R2、R4、R5、n、L、Z等如本文定义，它们的药物组合物和使用方法。这些新型化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地说，抑制Aβ肽的产生。本公开涉及用于治疗与β-淀粉样蛋白产生相关的神经疾病的化合物，如阿尔茨海默病和其他受抗淀粉样活性影响的疾病。
• 3-AMINO-1-INDANOLE, METHOD OF SYNTHESIZING THE SAME AND METHOD OF OPTICAL RESOLUTION
  申请人：——

  公开号：US20020177736A1

  公开（公告）日：2002-11-28

  The present invention relates to a compound which is expected to be a synthetic intermediate for medicines and pesticides or a separating agent for chromatography or a enantiomerically resolving agent for racemic bodies. That is, it provides 3-amino-1-indanol represented by the formula (I), a process for synthesizing it, an enantiomerically active compound of 3-amino-1-indanol and a process for enantiomerically resolving 3-amino-1-indanol, and a separating agent for enantiomeric isomers comprising enantiomerically active compound thereof as an effective ingredient. 1 In the formula, the configuration between OH group and NH 2 group are cis-configuration or trans-configuration and the compound may be a racemic body or an enantiomerically active compound.

  本发明涉及一种化合物，预计可用作药物和农药的合成中间体，或用作色谱分离剂或对手异构体分离剂。即，本发明提供了由公式（I）表示的3-氨基-1-吲哚醇，其合成过程，3-氨基-1-吲哚醇的对映体活性化合物及其对映体分离方法，以及包含其对映体活性化合物作为有效成分的对映体异构体分离剂。在公式中，OH基团和NH2基团之间的构型为顺式构型或反式构型，该化合物可以是一个对映体异构体或一个对映体活性化合物。
• Heterobicyclic metalloprotease inhibitors
  申请人：Nolte Bert

  公开号：US20080176870A1

  公开（公告）日：2008-07-24

  The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.

  本发明涉及含有杂环的药物，特别是含有杂环的金属蛋白酶抑制剂化合物。更具体地说，本发明提供了一类新的杂环金属蛋白酶抑制剂化合物，其相对于当前已知的金属蛋白酶抑制剂表现出更高的效力。